ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Verastem Inc

Verastem Inc (VSTM)

3.175
-0.075
( -2.31% )
Updated: 13:34:51

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.175
Bid
3.17
Ask
3.18
Volume
157,511
3.16 Day's Range 3.29
3.14 52 Week Range 14.22
Market Cap
Previous Close
3.25
Open
3.28
Last Trade
1
@
3.1704
Last Trade Time
13:36:35
Financial Volume
$ 505,196
VWAP
3.2074
Average Volume (3m)
728,114
Shares Outstanding
25,325,551
Dividend Yield
-
PE Ratio
-0.92
Earnings Per Share (EPS)
-3.45
Revenue
-
Net Profit
-87.37M

About Verastem Inc

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/... Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Verastem Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VSTM. The last closing price for Verastem was $3.25. Over the last year, Verastem shares have traded in a share price range of $ 3.14 to $ 14.22.

Verastem currently has 25,325,551 shares outstanding. The market capitalization of Verastem is $80.54 million. Verastem has a price to earnings ratio (PE ratio) of -0.92.

VSTM Latest News

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a...

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level was subsequently cleared...

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA...

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a...

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.495-13.48773841963.673.673.144908753.34240214CS
4-1.515-32.3027718554.695.253.1420510433.95998562CS
12-8.685-73.229342327211.8613.523.147281144.78828849CS
26-4.625-59.29487179497.814.223.144122476.06706009CS
52-6.565-67.40246406579.7414.223.142744576.74557103CS
156-53.885-94.435681738557.0658.563.14130952018.48125801CS
260-15.665-83.147558386418.8459.223.14212068622.23176111CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.7241
(140.56%)
298.67M
SHCRSharecare Inc
$ 1.3723
(77.21%)
38.71M
NXLNexalin Technologies Inc
$ 1.895
(72.27%)
46.33M
SPECSpectaire Holdings Inc
$ 0.56
(64.71%)
59.59M
MINMMinim Inc
$ 3.8734
(35.43%)
42.22M
FLFVFeutune Light Acquisition Corporation
$ 3.59
(-57.41%)
50.05k
KAVLKaival Brands Innovations Group Inc
$ 1.475
(-48.61%)
3.39M
PBMPsyence Biomedical Ltd
$ 0.408904
(-31.85%)
2.31M
RELIReliance Global Group Inc
$ 0.4739
(-21.53%)
7.79M
MYNZMainz BioMed NV
$ 0.44
(-21.43%)
555.85k
NVDANVIDIA Corporation
$ 126.355
(-3.38%)
319.36M
AREBAmerican Rebel Holdings Inc
$ 0.7244
(140.66%)
298.67M
CRKNCrown Electrokinetics Corporation
$ 0.0402
(-19.60%)
141.75M
NKLANikola Corporation
$ 0.3641
(10.47%)
134.32M
ASTIAscent Solar Technologies Inc
$ 0.1125
(4.26%)
115.22M

VSTM Discussion

View Posts
Termite7 Termite7 4 weeks ago
https://www.verastem.com/research/pipeline/ Good pipeline!!!
πŸ‘οΈ0
TheFinalCD TheFinalCD 4 weeks ago
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)

$VSTM 12 patients experienced treatment emergent serious adverse events, 11 patients with grade β‰₯3 pic.twitter.com/pY34tS6maD— Antonio (@WallStDayTrader) May 24, 2024
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)❓

Today Company announce that they will submit BLA for combo treatment only for a mutant subgroup, which significantly reduces the TAM

πŸ‘€ $XBI https://t.co/Au1lEsh0qU pic.twitter.com/LzSvNS1T7n— Dogtor (@Dogtor01416800) May 24, 2024
👍️ 1
TheFinalCD TheFinalCD 4 weeks ago
4.75 NOW VSTM over $18
πŸ‘οΈ0
pmach64 pmach64 4 weeks ago
Brutal morning sell off after what appeared to be good news.
πŸ‘οΈ0
tw0122 tw0122 4 weeks ago
VSTM over $18
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
VSTM over $10
πŸ‘οΈ0
Harbor6460 Harbor6460 12 months ago
Read about it at 3.00 it looks like.
πŸ‘οΈ0
muchogusto muchogusto 12 months ago
Worth reading
https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer
πŸ‘οΈ0
Harbor6460 Harbor6460 12 months ago
It’s death after a RS. Wait for 4.00 or way under. Then Good risk reward
πŸ‘οΈ0
muchogusto muchogusto 12 months ago
So, what is next for VSTM in terms of catalysts and results? Any upcoming data points? Is it now free from funding worries and free to focus on producing results? Tartia, your input would be appreciated.
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Happy I hit and run. I would consider this at under 4.00
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
They definite are diluting. They need money. But in long run great for shareholder
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
highest volume in history -insert dd-
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Yep
πŸ‘οΈ0
knrorrel knrorrel 1 year ago
nice
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 year ago
oh my
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Looks like dilution
πŸ‘οΈ0
KeepOn KeepOn 1 year ago
Looks like real support at a dollar. Could be ready for next leg.
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Added the dip
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
I post so others can ride with me to the victory circle so to speak.
I really like it when peeps get a good run.
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
VSTM: Well, Capt. T-N, you certainly scored MONSTER TIME on this one today, Dude!!! (EASY money for you, or WHAT, Bro!!! CONGRATS!!!)
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Halted?
πŸ‘οΈ0
jchords jchords 1 year ago
Nice call
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Okay nice run folks
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
.75 comin up

1.00 soon
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
LV2 still looks real thin
.75 ?
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Really Good Friday here
πŸ‘οΈ0
power11 power11 1 year ago
WHAT NEWS ??????
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
I’d be nice waking up to thirty bucks a share from this level
πŸ‘οΈ0
shurtha2000 shurtha2000 1 year ago
This kind of news you can skip PHASEIII and go straight to approval
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
Next week it should run strong.
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
This news is very positive
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Peeps see double tops and think sell
Just bust through it
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
You would think.
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
Break past .52 come on
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Insiders are buying options. Time to load imo. Could see 2.00-3.00 like nothing
πŸ‘οΈ0
SaltyOne SaltyOne 1 year ago
I'm with you on this one and so are the Baker Bros
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Never seen a board that nobody post wtf. Lol. We got things coming imo
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
2 million volume yesterday. That’s a fund imo. I told you this was coming. Price of a stock does not reflect market value. This combo of drugs is a monster. I see 5-15.00 by Jan 2025
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
In addition to the progress with avutometinib + defactinib in LGSOC ONCT is moving two KRAS-G12C projects forward: avutometinib + sotorasib and avutometinib + adagrasib in KRAS-(G12C) NSCLC. Preclinical data suggests that we should see synergy with these combinations. I believe that the avuto + soto initial readout should happen at any time and this will be a big deal if the data is encouraging. In the preclinical data VSTM demonstrated that the synergistic effect of avutometinib + a G12C inhibitor was further enhanced with the addition of defactinib. I hope that they advance this G12C program with both the doublet and the triplet approach.

Clinical progress with the LGSOC program and the KRAS-G12C programs justify a much higher market cap than we have now. Any success with pancreatic cancer would be a total game-changer. The LGSOC and KRAS-G12C programs and low market cap provide a low risk opportunity to be in on the big prize which is Pancreatic cancer.
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
The RAMP201 and FRAME data for LGSOC is excellent so far. We should have final data readout in about 18 months (IMO). This data is expected to support an AA filing with the FDA for LGSOC. The current PPS does not reflect the significance of this. In addition, we have near term pending data on RAMP203 for RAS(G12C) NSCLC. Positive results with RAMP203 will further enhance value and help establish Avutometinib as a valid approach to RAS pathway cancers.

As an aside, I have my eyes on Akena's RAF:MEK clamp which may be even better than Avutometinib. The only problem is that Akena's molecule is several years behind Avuto in development.
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
I think that anyone interested needs to follow-up reading this PR by listening to the webcast presentation. It provides a more granular and encouraging overview than the PR alone does. I felt much more encouraged after hearing the overview and seeing the slides.

For instance the 28% ORR is interim data, not fully matured data. If one includes the 3 unconfirmed PRs the ORR is 38%. That's very good. If approved there will be TWO drugs approved.
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 1 year ago
Regulatory Update Following Type B FDA Meeting on LGSOC Program

A recent FDA meeting was held to discuss the encouraging results to date of the ongoing RAMP 201 trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirm the go forward treatment regimen selection and discuss the regulatory path forward. The combination of avutometinib with defactinib has been selected vs monotherapy as the go forward treatment in all recurrent LGSOC regardless of KRAS status, acknowledging the demonstrated contribution of defactinib.

The Company intends to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust to potentially support filing for accelerated approval. Both studies are evaluating avutometinib and defactinib in patients with recurrent LGSOC. The Company is in ongoing discussions with the FDA on the confirmatory study and plans to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study.

β€œWe appreciate the productive and ongoing discussions with the FDA regarding the progress of our LGSOC program, including the alignment around key next steps as part of our breakthrough therapy designation,” said Brian Stuglik, CEO of Verastem Oncology. β€œWith the encouraging results of the RAMP 201 Part A interim analysis and the FRAME study, we will work expeditiously to prepare to file for an accelerated approval that encompasses the totality of the data from both trials as well as progress on the confirmatory study.”

https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-data-and-regulatory-update
πŸ‘οΈ0
Tartiaboy Tartiaboy 1 year ago
I already one a nice chunk. Listened to the webcast. Data looks very impressive. Open to discussing it.
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 1 year ago
Ramp 201 Data Updated, and a Private Placement secured.

BUY
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Looks like Big mews coming in next 3-6 months
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 2 years ago
Well, not time like the present to start a position, I doubt it can get much worse except go to $0.....

Still waiting on some results that will make or break this tiny Biotech.
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Nobody posts. But i know its coming. Boommmmmmm
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
I thinkthis is a HR. 90 mil cash. At these prices look in 5 years. 10-20x money. They drug is good iMo
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 2 years ago
I imagine hedge funds are unloading their losses before the next round of bad news comes. This one was a 100% shock disappointment
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock